TR200200401T2 - Mycophenolate mofetil with PEG-IFN-a - Google Patents

Mycophenolate mofetil with PEG-IFN-a

Info

Publication number
TR200200401T2
TR200200401T2 TR2002/00401T TR200200401T TR200200401T2 TR 200200401 T2 TR200200401 T2 TR 200200401T2 TR 2002/00401 T TR2002/00401 T TR 2002/00401T TR 200200401 T TR200200401 T TR 200200401T TR 200200401 T2 TR200200401 T2 TR 200200401T2
Authority
TR
Turkey
Prior art keywords
ifn
peg
mycophenolate mofetil
treatment
therapeutically effective
Prior art date
Application number
TR2002/00401T
Other languages
Turkish (tr)
Inventor
Catherine Graves Mary
Ghristopher Pappas Stephen
Zahm Friederike
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of TR200200401T2 publication Critical patent/TR200200401T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Mikofenolik asidin farmasötik açidan kabul edilebilir bir tuzu veya ön ilacindan terapötik olarak etkili bir miktar ile birlikte IFN-a veya PEG-IFN-a'dan terapötik olarak etkili bir miktarin karaciger hastaliklari hastalarinin tedavi edilmesi amaçli ilaçlarin üretilmesinde kullanilmasi. Bilesenler en azindan adi geçen hastanin dis kaninda bulunan HCV-RNA miktarini, tedavi bittikten sonra 24.haftada 100 kopya/ml'nin altina indirmek için yeterli bir süreyle birlikte verilir.The use of a therapeutically effective amount of a pharmaceutically acceptable salt or prodrug of mycophenolic acid, as well as a therapeutically effective amount of IFN-a or PEG-IFN-a, in the manufacture of medicaments for the treatment of patients with liver disease. The components are given together for a sufficient time to reduce the amount of HCV-RNA present in the outer blood of the named patient, below 100 copies / ml at 24 weeks after treatment.

TR2002/00401T 1999-08-13 2000-08-08 Mycophenolate mofetil with PEG-IFN-a TR200200401T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99115950 1999-08-13
US18790700P 2000-03-08 2000-03-08

Publications (1)

Publication Number Publication Date
TR200200401T2 true TR200200401T2 (en) 2002-06-21

Family

ID=29762814

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00401T TR200200401T2 (en) 1999-08-13 2000-08-08 Mycophenolate mofetil with PEG-IFN-a

Country Status (14)

Country Link
EP (1) EP1220683A2 (en)
JP (1) JP2003507339A (en)
CN (1) CN1368887A (en)
AU (1) AU7408200A (en)
BR (1) BR0013252A (en)
CA (1) CA2380653A1 (en)
HU (1) HUP0202525A3 (en)
MX (1) MXPA02001296A (en)
PE (1) PE20010490A1 (en)
PL (1) PL357367A1 (en)
RU (1) RU2002105485A (en)
TR (1) TR200200401T2 (en)
WO (1) WO2001012214A2 (en)
ZA (1) ZA200200280B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
SI1719773T1 (en) 2004-02-24 2009-08-31 Japan Tobacco Inc Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor
US7632491B2 (en) * 2004-08-12 2009-12-15 Schering Corporation Stable pegylated interferon formulation
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
WO2010110503A1 (en) * 2009-03-27 2010-09-30 주식회사 중외제약 INTERFERON-α (IFN-α) FUSED PROTEIN HAVING IFN-α AND CYTOPLASMIC TRANSDUCTION PEPTIDE (CTP)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012013117U1 (en) 2011-10-21 2015-01-16 Abbvie Inc. Combination treatment (e.g., with ABT-072 or ABT-333 from DAAs for use in the treatment of HCV)
DE112012003510T5 (en) 2011-10-21 2015-03-19 Abbvie Inc. Method for the treatment of HCV comprising at least two direct-acting antiviral agents, ribavirin but not interferon
JP6820841B2 (en) * 2014-11-06 2021-01-27 ファーマエッセンティア コーポレイション Dosing regimen for pegged interferon
CN109689063A (en) 2016-04-28 2019-04-26 埃默里大学 Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases

Also Published As

Publication number Publication date
MXPA02001296A (en) 2002-07-22
PL357367A1 (en) 2004-07-26
CN1368887A (en) 2002-09-11
WO2001012214A3 (en) 2001-10-04
WO2001012214A2 (en) 2001-02-22
RU2002105485A (en) 2004-01-27
EP1220683A2 (en) 2002-07-10
JP2003507339A (en) 2003-02-25
AU7408200A (en) 2001-03-13
PE20010490A1 (en) 2001-04-27
BR0013252A (en) 2002-04-16
CA2380653A1 (en) 2001-02-22
ZA200200280B (en) 2003-04-11
HUP0202525A3 (en) 2003-11-28
HUP0202525A2 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
RU2003119460A (en) APPLICATION OF PEG-INTERFERON-A (PEG-INF-A) AND RIBAVIRIN FOR TREATMENT OF CHRONIC HEPATITIS C
TR200200401T2 (en) Mycophenolate mofetil with PEG-IFN-a
ATE219363T1 (en) SOLUBLE PRODRUGS OF PACLITAXEL
DK275488A (en) indolone derivatives
BRPI0108977B8 (en) azacyclic compounds, pharmaceutical composition and use of a compound or pharmaceutically acceptable salt thereof
ES2169762T3 (en) CONTINUOUS RELEASE OF PEPTIDES FROM PHARMACEUTICAL COMPOSITIONS.
KR920700200A (en) 19-nor-vitamin D compound
ES2178430T3 (en) USE OF GELIFICABLE PHARMACEUTICAL COMPOSITIONS IN PARODONTOLOGY.
IL112667A0 (en) 6-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
ATE87484T1 (en) PHYSIOLOGICALLY ACTIVE SUBSTANCES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
TR200101633T2 (en) Pharmaceutical composition
KR970025615A (en) Cancer metastasis inhibitor
ATE257704T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING NORASTEMIZOLE.
NO20003313D0 (en) Therapeutic agents
RU2004137823A (en) THERAPEUTIC AGAINST HYPERCALCEMIC CRISIS
AR012731A1 (en) USE OF A TAXANE DERIVATIVE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, USE OF A BIODICABILITY IMPROVEMENT AGENT OF SUCH A DERIVATIVE ORAL DOSAGE FORM AND UNDERSTANDING ITEM AND METHOD FOR FORMING A BIO-AVAILABLE ACTIVE AGENT.
KR830002510A (en) Composition consisting of biologically active compound and hydroxyalkyl starch
ES2111352T3 (en) USE OF DIESTER PHOSPHATE FOR THE TREATMENT OF RETINAL DISEASES.
JP2002544227A5 (en)
RU2004131214A (en) METHODS FOR TREATING COGNITIVE DISORDERS
AR025549A1 (en) MICOFELONATE MOFETIL IN ASSOCIATION WITH PEG-IFN-ALFA
KR890012942A (en) 5-substituted ornithine derivatives
RU2006101061A (en) ASENAPINE FOR THE TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH OVERBODY WEIGHT OR PREPAREDNESS FOR OVERWEIGHT BODY
YU9302A (en) Mycophenolate mofetil in association with peg-ifn-alpha